Search results for "Gens"

showing 10 items of 3762 documents

Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohor…

2020

Abstract Background Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or early termination of chemotherapy due to oxaliplatin toxicity, which may increase the risk of early recurrence. The objective of this study was to analyze the relationship between the relative dose intensity of oxaliplatin (RDI-O) and early recurrence among stage III CC patients. Methods The study included 365 patients treated at five oncology centers in Poland between 2000 and 2014. Survival analysis was performed using the Kaplan-Meier method. Univariate analysis…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGeneticsAdjuvant therapyMedicineHumans030212 general & internal medicineRelative dose intensityRC254-282Survival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryCumulative doseProportional hazards modelNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyMiddle Agedmedicine.diseaseCumulative doseOxaliplatinColon cancerAdjuvant chemotherapyOxaliplatinOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsFemaleNeoplasm Recurrence Localbusinessmedicine.drugResearch Article
researchProduct

Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis

1998

BACKGROUND None of the commonly used staging criteria accurately determine the prognosis of a patient with adenocarcinoma of Barrett's esophagus. The authors therefore assessed the expression pattern and prognostic impact of CD44 standard and CD44 isoforms CD44v4, v5,v6,v7, and v10 in adenocarcinoma of Barrett's esophagus. METHODS Specimens from 41 patients with adenocarcinoma of Barrett's esophagus who underwent esophageal resection were embedded in paraffin and studied immunohistochemically to determine the expression of CD44 splice variants. Histomorphologic parameters and survival time were not known at the time of the investigation. RESULTS Correlations between favorable clinical or hi…

AdultMaleCancer Researchmedicine.medical_specialtyEsophageal NeoplasmsAdenocarcinomaGastroenterologyBarrett EsophagusAntigens NeoplasmInternal medicineBiopsymedicineHumansEsophagusAgedGlycoproteinsAnalysis of Variancebiologymedicine.diagnostic_testbusiness.industryEsophageal diseaseCD44CancerMiddle Agedmedicine.diseasedigestive system diseasesHyaluronan Receptorsmedicine.anatomical_structureOncologyBarrett's esophagusbiology.proteinAdenocarcinomaFemaleComplicationbusinessCancer
researchProduct

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

2005

BACKGROUND In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). METHODS Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, Phase II studies. Patients received monotherapy with GO 9 mg/m2 as a 2-hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS Two hundred seventy-seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as ≤ 5% blasts in the bone marrow wit…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidMaximum Tolerated DoseGemtuzumab ozogamicinmedicine.medical_treatmentCD33Sialic Acid Binding Ig-like Lectin 3Antigens Differentiation MyelomonocyticHematopoietic stem cell transplantationNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleClinical Trials Phase II as TopicAntigens CDRecurrenceInternal medicinemedicineHumansSingle-Blind MethodSurvival rateAgedAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseGemtuzumabSurgerySurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureAminoglycosidesTreatment OutcomeOncologyEvaluation Studies as TopicFemalebusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis.

1997

BACKGROUND. Basaloid squamous cell carcinoma (BSCC) is a recently recognized, poorly differentiated variant of squamous cell carcinoma (SCC), which is located predominantly in the upper aerodigestive tract. METHODS. In this study, clinical and pathologic parameters of 17 BSCCs and 133 typical SCCs of the esophagus that underwent potentially curative resection (no distant metastases, no residual tumor) were compared. In addition, light microscopic, electron microscopic, and immunohistochemical features of BSCC were investigated, to determine whether this type of carcinoma could be differentiated from other poorly differentiated carcinomas of the esophagus. RESULTS. Light microscopic study sh…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyEsophageal NeoplasmsApoptosisEpitheliumDiagnosis DifferentialCytokeratinNecrosisSex FactorsCarcinoma BasosquamousmedicineCarcinomaHumansNeoplasm InvasivenessEsophagusBasaloid Squamous Cell CarcinomaAgedNeoplasm StagingAged 80 and overMucous Membranebusiness.industryCarcinoma in situS100 ProteinsAge FactorsCell DifferentiationMiddle Agedmedicine.diseasePrognosisAntigens DifferentiationImmunohistochemistryActinsSurvival Ratestomatognathic diseasesMicroscopy Electronmedicine.anatomical_structureOncologyEpidermoid carcinomaDysplasiaCarcinoma Squamous CellKeratinsHistopathologyFemalebusinessCarcinoma in SituCell DivisionCancer
researchProduct

CONSISTENT BONE MARROW-DERIVED CELL MOBILIZATION FOLLOWING REPEATED SHORT COURSES OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH AMYOTROPH…

2009

Background and aims. The aim of this study was to evaluate and characterize the feasibility and safety of bone marrow-derived cell (BMC) mobilization following repeated courses of granulocyte-colony stimulating factor (G-CSF) in patients with amyotrophic lateral sclerosis (ALS). Methods. Between January 2006 and March 2007, 26 ALS patients entered a multicenter trial that included four courses of BMC mobilization at 3-month intervals. In each course, G-CSF (5 mu g/kg b.i.d.) was administered for four consecutive days; 18% mannitol was also given. Mobilization was monitored by flow cytometry analysis of circulating CD34(+) cells and by in vitro colony assay for clonogenic progenitors. Co-exp…

AdultMaleCancer Researchmedicine.medical_specialtySLa - trial clinico - C-GSFImmunologyAntigens CD34Bone Marrow CellsDrug Administration ScheduleColony-Forming Units AssayCell MovementInternal medicineMulticenter trialmedicineImmunology and AllergyHumansCell LineageProspective StudiesAmyotrophic lateral sclerosisProspective cohort studyGenetics (clinical)Hematopoietic Stem Cell MobilizationNeuronsTransplantationMobilizationbusiness.industryStem CellsAmyotrophic Lateral SclerosisGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsBone Marrow-Derived CellHematopoietic Stem Cell MobilizationSurgeryGranulocyte colony-stimulating factorNerve RegenerationSettore MED/26 - NEUROLOGIAGranulocyte macrophage colony-stimulating factorTreatment OutcomeOncologyBiological MarkersFemalebusinessNeurogliaBiomarkersmedicine.drug
researchProduct

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

2004

Contains fulltext : 57114.pdf (Publisher’s version ) (Closed access) Chimeric monoclonal antibody G250 (WX-G250) binds to a cell surface antigen found on >90% of renal cell carcinoma (RCC). A multicentre phase II study was performed to evaluate the safety and efficacy of WX-G250 in metastatic RCC (mRCC) patients. In all, 36 patients with mRCC were included. WX-G250 was given weekly by intravenous infusion for 12 weeks. Patients with stable disease (SD) or response were eligible to receive additional treatment for 8 weeks. None of the 36 enrolled patients experienced any drug-related grade III or IV toxicity. Only three patients had grade II toxicity possibly related to the study medication.…

AdultMaleCancer Researchmedicine.medical_specialtyrenal cell carcinomaRecombinant Fusion ProteinsPhases of clinical researchAntineoplastic AgentsGastroenterologyClinicalMonoclonal antibody G250Renal cell carcinomaInternal medicinemedicineCarcinomaHumansProspective StudiesCarcinoma Renal CellAgedbusiness.industryGirentuximabAntibodies MonoclonalImmunotherapy gene therapy and transplantation [UMCN 1.4]CA-IXMiddle Agedmedicine.diseaseKidney NeoplasmsSurgeryClinical trialTreatment OutcomeOncologymonoclonal antibodyAntigens SurfaceFemaleimmunotherapybusinessWX-G250Progressive diseasemedicine.drugKidney disease
researchProduct

Expression of cysteine proteinases cathepsins B and K and of cysteine proteinase inhibitor cystatin C in giant cell tumor of tendon sheath.

2001

The expression of cysteine proteinases cathepsins B and K and of the endogenous inhibitor of cysteine proteinases, cystatin C, was investigated in tissue specimens of patients with giant cell tumor of tendon sheath (GCTTS). Expression of both enzymes was examined by immunohistochemistry in tissue specimens of 14 patients with GCTTS. Applying double-labeling techniques, the coexpression of cathepsin B and its major endogenous inhibitor cystatin C was additionally studied. Cells expressing the respective proteins were further characterized with the macrophage markers HAM56 and anti-CD68 (clone PG-M1). Cathepsin B could be detected in numerous HAM56-positive mononuclear cells (MC), but only in…

AdultMaleCathepsin KAntigens Differentiation MyelomonocyticCathepsin ECell CountCathepsin FBiologyCysteine Proteinase InhibitorsGiant CellsCathepsin BPathology and Forensic MedicineCathepsin CCathepsin BImmunoenzyme TechniquesTendonsCathepsin OCathepsin HAntigens CDCathepsin L1HumansCystatin CCathepsin SAgedMuscle NeoplasmsGiant Cell TumorsAntibodies MonoclonalMiddle AgedMolecular biologyCathepsinsCystatinsBiochemistryLeukocytes MononuclearFemaleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

Modifications of general parameters of immune activation in the sera of Sicilian patients with Boutonneuse fever

1998

SUMMARYThe serum levels of β2-microglobulin (β2-M), soluble HLA class I antigen (sHLA-I), soluble CD4 (sCD4) and CD8 (sCD8) were studied in 98 Sicilian patients with Boutonneuse fever (BF). In different stages of infection all markers were significantly increased in sera from Sicilian patients with acute BF compared with healthy controls. sCD8 and sHLA-I reached the peak in the second week after the onset of symptoms, whereas sCD4 and β2-M reached the peak in the first week. Afterwards sCD8 decreased to the levels of controls within the third week, the other parameters decreased later and were unmodified until the third week of infection. Significant correlations were found between sCD4 and…

AdultMaleCellular immunityCD8 AntigensCD3ImmunologyBoutonneuse FeverImmune systemT-Lymphocyte SubsetsmedicineHumansImmunology and AllergyAgedbiologyBeta-2 microglobulinHistocompatibility Antigens Class IMiddle Agedmedicine.diseasebiology.organism_classificationBoutonneuse feverRickettsiaSolubilityCD4 AntigensImmunologybiology.proteinFemaleOriginal Articlebeta 2-MicroglobulinRickettsia conoriiCD8Clinical and Experimental Immunology
researchProduct

Lack of evidence of hepatitis in patients with oral lichen planus in China: A case control study

2016

Background: China has been one of the countries with high prevalence of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) liver disease. And lichen planus is an extrahepatic manifestation of patients with chronic HCV infection. This case-control study was conducted to investigate the relationship between oral lichen planus (OLP) and HBV/HCV infection in China. Material and Methods: A total of 776 patients, including 150 patients with OLP (Group OLP), 429 inpatients from the Trauma Ward of Oral and Maxillofacial Surgery Department (Group A), 110 patients with other oral mucosal diseases, but without a reported association with HCV infection (Group B) and 87 patients with oral liche…

AdultMaleChinamedicine.medical_specialtyHepatitis C virusOdontologíamedicine.disease_causeGastroenterologyVirusHepatitis B Antigens030207 dermatology & venereal diseases03 medical and health sciencesLiver diseaseHepatitis B Chronic0302 clinical medicinestomatognathic systemInternal medicineHumansMedicineGeneral DentistryHepatitis B virusHepatitisOral Medicine and Pathologyintegumentary systembusiness.industryResearchvirus diseases030206 dentistryHepatitis CHepatitis C AntibodiesHepatitis C ChronicMiddle AgedHepatitis B:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludVirologydigestive system diseasesstomatognathic diseasesOtorhinolaryngologyCase-Control StudiesUNESCO::CIENCIAS MÉDICASFemaleSurgeryOral lichen planusbusinessLichen Planus OralMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Lower strength of the human posterior patellar tendon seems unrelated to mature collagen cross-linking and fibril morphology

2009

The human patellar tendon is frequently affected by tendinopathy, but the etiology of the condition is not established, although differential loading of the anterior and posterior tendon may be associated with the condition. We hypothesized that changes in fibril morphology and collagen cross-linking would parallel differences in material strength between the anterior and posterior tendon. Tendon fascicles were obtained from elective ACL surgery patients and tested micromechanically. Transmission electron microscopy was used to assess fibril morphology, and collagen cross-linking was determined by HPLC and calorimetry. Anterior fascicles were markedly stronger (peak stress: 54.3 ± 21.2 vs.…

AdultMaleCollagen cross linkingPhysiologybusiness.industryFibrillar CollagensPatellar ligamentAnatomyFibrilmedicine.diseasePatellar tendonTendonStructure-Activity RelationshipCross-Linking Reagentsmedicine.anatomical_structurePatellar LigamentTensile StrengthPhysiology (medical)HumansMedicineStress MechanicalTendinopathybusinessFibril morphologyJumper's kneeJournal of Applied Physiology
researchProduct